early childhood health outcomes following in utero ... · annette k. regan, phda,b,g context:...
TRANSCRIPT
Early Childhood Health OutcomesFollowing In Utero Exposure toInfluenza Vaccines: ASystematic ReviewDamien Y.P. Foo, BSc (Hons),a,b Mohinder Sarna, PhD,a,b Gavin Pereira, PhD,a,c,d Hannah C. Moore, PhD,b Deshayne B. Fell, PhD,e,f
Annette K. Regan, PhDa,b,g
abstractCONTEXT: Vaccination during pregnancy is an effective strategy for preventing infant disease;however, little is known about early childhood health after maternal vaccination.
OBJECTIVES: To systematically review the literature on early childhood health associated withexposure to influenza vaccines in utero.
DATA SOURCES: We searched CINAHL Plus, Embase, Medline, Scopus, and Web of Science forrelevant articles published from inception to July 24, 2019.
STUDY SELECTION: We included studies published in English reporting original data withmeasurement of in utero exposure to influenza vaccines and health outcomes among children,5 years of age.
DATA EXTRACTION: Two authors independently assessed eligibility and extracted data on studydesign, setting, population, vaccines, outcomes, and results.
RESULTS: The search yielded 3647 records, of which 9 studies met the inclusion criteria. Studiesexamined infectious, atopic, autoimmune, and neurodevelopmental outcomes, and all-causemorbidity and mortality. Authors of 2 studies reported an inverse association betweenpandemic influenza vaccination and upper respiratory tract infections, gastrointestinalinfections, and all-cause hospitalizations; and authors of 2 studies reported modest increasedassociation between several childhood disorders and pandemic or seasonal influenzavaccination, which, after adjusting for confounding and multiple comparisons, were notstatistically significant.
LIMITATIONS: Given the small number of studies addressing similarly defined outcomes, meta-analyses were deemed not possible.
CONCLUSIONS: Results from the few studies in which researchers have examined outcomes inchildren older than 6 months of age did not identify an association between exposure toinfluenza vaccines in utero and adverse childhood health outcomes.
aSchool of Public Health, Curtin University, Perth, Western Australia, Australia; bWesfarmers Centre of Vaccines & Infectious Diseases, cTelethon Kids Institute, The University of WesternAustralia, Perth, Western Australia, Australia; dCentre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway; eSchool of Epidemiology and Public Health, University ofOttawa, Ottawa, Ontario, Canada; fChildren’s Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada; and gSchool of Public Health, Texas A&M University, College Station, Texas
To cite: Foo DYP, Sarna M, Pereira G, et al. Early Childhood Health Outcomes Following In Utero Exposure to Influenza Vaccines: A Systematic Review. Pediatrics.2020;146(2):e20200375
PEDIATRICS Volume 146, number 2, August 2020:e20200375 REVIEW ARTICLE by guest on January 12, 2021www.aappublications.org/newsDownloaded from
Influenza is a major respiratoryinfection that can lead to severeillness and death at any age,1 buthigh-risk populations such aspregnant women and infants,6 months of age have a greater riskof severe illness.2,3 No vaccines arecurrently licensed for infants in thisage group.4–6 Because maternalantibodies cross the placenta duringpregnancy,7 influenza vaccinesadministered to pregnant women arean effective means of protecting bothmothers and their infants frominfluenza infection.8–10 Given thesebenefits, the 2012 World HealthOrganization position paper oninfluenza vaccines recommendedpregnant women be considered thehighest priority risk group forcountries considering expansionof their seasonal influenzavaccination program.6 Globally,.50% of countries have policiesrecommending influenza vaccines topregnant women.6,11–14
Despite these widespreadrecommendations, vaccine uptake ispoor in many countries,15–22 withconcerns around vaccine safety citedas the most common reason forvaccine hesitancy.23 These concernsstand in contrast to the substantialevidence supporting the safety ofadministration of inactivatedinfluenza vaccines (IIVs) duringpregnancy on maternal, fetal, andearly infant outcomes. The safety ofinfluenza vaccination duringpregnancy has been consistentlyhighlighted in systematic reviewsand meta-analyses.24–26 Thesestudies concluded that influenzavaccination during pregnancy wasnot associated with increased riskof congenital anomalies, stillbirth,preterm birth, fetal growthrestriction, and/or low birthweight.24–27 Although a recentreview assessed influenza andother respiratory outcomes inearly childhood, no study hascomprehensively assessed longer-term child health outcomes in
association with in utero exposure toIIV.28
METHODS
We conducted a systematic review ofthe literature related to IIV duringpregnancy and childhood healthoutcomes, as guided by the minimumevidence-based set of items forreporting in systematic reviewsoutlined in the Preferred ReportingItems for Systematic Reviewsand Meta-Analyses (PRISMA)guidelines.29 The study protocol wasregistered with the National Institutefor Health Research internationalprospective register of systematicreviews (CRD42014014384) beforecommencing the review.
Data Sources and Search Strategy
We searched CINAHL Plus, Embase,Medline, Scopus, and Web of Sciencedatabases for peer-reviewedliterature from inception to July 24,2019, using a combination of medicalsubject headings and keywordsrelated to prenatal influenzavaccination and early childhoodhealth outcomes (SupplementalTables 6–10). Our search includedexperimental and observationalstudies, including cross-sectional,case-control, and cohort studies. Asrecommended,30,31 we consulted witha medical librarian to develop oursearch strategy.
Study Selection
Eligible studies included thoseinvestigating any mother–child pairpopulation, in which exposure toinfluenza vaccines in utero (pandemicor seasonal) was reported, anunexposed mother–child pair controlgroup is present, and $1 healthoutcome in children aged 6 months to5 years was investigated. We madethe following exclusions: articles notpublished in peer-reviewed journals,articles published in languages otherthan English, studies not conducted inhumans, reviews, editorials,commentaries, letters, case studies,
and case series. First, twoindependent reviewers (D.Y.P.F. andM.S.) screened and reviewed the titlesand abstracts of records retrievedduring the search for inclusioncriteria. Second, the reviewersscreened and reviewed the full-textarticles for eligibility in accordancewith study inclusion and exclusioncriteria. Studies deemed to meet theinclusion criteria by the tworeviewers were included in the finalreview. A third reviewer (A.K.R.)resolved any conflicts between thetwo reviewers during each screeningand review stage.
Data Extraction and Risk-of-BiasAssessment
We developed a standardized datacollection form to extract informationon study characteristics, includingstudy design, geographic location,participant demographics, definitionand ascertainment of exposure andoutcomes (including type of influenzavaccine), effect sizes and confidenceintervals (CIs), and confoundingvariables. Two reviewers (D.Y.P.F.and M.S.) independently extractedinformation from each of the includedarticles.
For observational studies, we usedthe Newcastle–Ottawa scale to assessrisk of bias (Tables 1–3).32 TheNewcastle–Ottawa scale hasa maximum score of 9, with a greaterscore indicating the lowest risk ofbias. The scoring system is based onthe following criteria: selection bias(maximum score: 4), comparability ofstudy groups (maximum score: 2),and ascertainment of exposure forcase-control studies or outcome forobservational studies (maximumscore: 3).32 Observational studieswere considered at low risk of bias ifthey scored $8 and moderate-highrisk of bias if they scored ,8.
For randomized controlled trials(RCTs), we used the Cochrane risk-of-bias tool to assess risk of bias.31 TheCochrane risk-of-bias tool addressed5 major domains: selection bias
2 FOO et al by guest on January 12, 2021www.aappublications.org/newsDownloaded from
(random sequence generation andallocation concealment), performancebias (blinding of participants andpersonnel and other potential threatsto validity), detection bias (blindingof outcome assessment and otherpotential threats to validity), attritionbias (incomplete outcome data), andreporting bias (selective outcomereporting).31 Consistent with theCochrane risk-of-bias tool scoring,articles were classified as low risk
of bias, some concerns of bias, orhigh risk of bias.31 Two reviewers(D.Y.P.F. and M.S.) independentlyassessed the quality of case-controland cohort studies and RCTsusing the Newcastle–Ottawa Scale42
and Cochrane risk-of-bias tool,43
respectively. Any conflicts betweenthe two reviewers during thequality assessment process wereresolved by a third reviewer(A.K.R.).
Data Synthesis and Analysis
We developed a narrative descriptionof the characteristics and results ofincluded studies. Where possible,results were provided by trimester ofvaccination and type of vaccine. Togenerate pooled effect estimates foreach outcome, a random effectsmeta-analysis was planned a priori,dependent on whether a sufficientnumber of studies were retrieved usingcommonly defined end-points (n . 2).
TABLE 1 Results of Risk-of-Bias Assessment for Cohort Studies
CohortStudiesa
OverallRisk-of-Biasscore
Riskof
Biasb
Criteria
Selection Comparabilityc Outcome
Representativenessof the Exposed
Cohort
Selection ofthe
NonexposedCohort
Ascertainmentof Cases
Outcome ofInterestWas NotPresent at
Startof Study
Comparabilityof the Designand Analysisfor Cohorts
Assessmentof Outcome
SufficientFollow-upDuration
Adequacyof Follow-
upof Cohorts
van Santenet al33
(2013)
6 of 9 High — X X X X X X —
Ludvigssonet al34
(2015)
8 of 9 Low X X X X XX X X —
van derMaaset al35
(2016)
7 of 9 High — X — X XX X X X
Fell et al36
(2016)8 of 9 Low X X X X XX X X —
Zerbo et al37
(2017)7 of 9 High — X X X XX X X —
Hviid et al38
(2017)8 of 9 Low X X X X XX X X —
Walsh et al39
(2019)8 of 9 Low X X X X XX X X —
a Cohort studies were assessed using the Newcastle–Ottawa scale. Each X represents whether an individual criterion is satisfied. Each — represents whether an individual criterion isnot satisfied.b Low risk of bias: overall risk of bias score $8; high risk of bias: overall risk of bias score ,8.c All criteria receives a maximum score of 1 X except for comparability of study groups where an additional X may be allocated for the control of additional important confounders.30
TABLE 2 Results of Risk-of-Bias Assessment for Case-Control Studies
Case-ControlStudiesa
OverallRisk-of-BiasScore
Riskof
Biasb
Selection Comparabilityc Exposure
Representativenessof the Cases
Selectionof theControls
Adequacyof CaseDefinition
Definitionof
Controls
Comparabilityof the Designand Analysisfor Cohorts
Ascertainmentof
Exposure
Comparability ofAscertainmentof Exposurefor Cohorts
Comparabilityof Nonresponse
Ratefor Cohorts
Benowitzet al40
(2010)
7 of 9 High X — X X X X X X
a Case-control studies were assessed using the Newcastle–Ottawa scale. Each X represents whether an individual criterion is satisfied. Each— represents whether an individual criterionis not satisfied.b Low risk of bias: overall risk of bias score $8; high risk of bias: overall risk of bias score ,8.c All criteria receives a maximum score of 1 X except for comparability of study groups where an additional X may be allocated for the control of additional important confounders.30
PEDIATRICS Volume 146, number 2, August 2020 3 by guest on January 12, 2021www.aappublications.org/newsDownloaded from
Role of the Funding Source
This systematic review wassupported in part by funding receivedfrom the National Health and MedicalResearch Council (GNT1141510),Curtin University Graduate ResearchSchool, and the Wesfarmers Centreof Vaccines & Infectious Diseasesat the Telethon Kids Institute. Thefunders had no role in the design orimplementation of the systematicreview or the decision to publishfindings from the review.
RESULTS
Study Selection
We identified 3647 records, of which3551 were excluded after initial titleand abstract screening. We reviewed96 full-text articles, of which 9 weredeemed eligible for inclusion (Fig 1).Reasons for exclusions included nomeasurement of influenza vaccinationduring pregnancy (n = 4), no reportedoutcome measure of early childhoodhealth (n = 33), not a comparativeobservational study or RCT (n = 44),or not published in English (n = 6).
Study Characteristics
Of the 9 included studies,methodology and study outcomeswere highly diverse (Table 4). All ofthe studies originated from high-income countries in NorthAmerica33,36,37,39,40 (n = 5) orEurope34,35,38,41 (n = 4), and studyperiods ranged between 1980 and2012. Estimates from the samepopulation were reported in 2
articles.33,37 One study was an RCT,41
5 studies were retrospective cohortstudies, 33,35,36,38,39 and 2 wereprospective cohort studies34,37; 1study used a case-control design.40
Record linkage was used in moststudies to measure prenatal influenzavaccination and early childhoodhealth outcomes (n = 7). Studiesranged in sample size from 306 to275 500 mother–infant pairs. Withthe exception of 1 study in whichchildren 6 to 12 months of age werespecifically examined,40 the follow-upperiod of included studies began atbirth and ranged from 1 to 15 yearsof age.
Exposure Assessment
Researchers in 6 studies investigatedpandemic34,36,38,39,41 influenzavaccines, and researchers in 3investigated seasonal33,37,40 influenzavaccines (Table 4). Of the 6 studies on2009 monovalent pandemic influenzaA virus subtype H1N1 (A/H1N1)vaccines, researchers of 4 studiesexclusively investigated adjuvantedvaccines (MF59-adjuvant: n = 235,41;AS03-adjuvant: n = 234,38).Vaccination status during pregnancywas ascertained by self-report (n =1),35 random allocation (n = 1),41
written or electronic health records(n = 3),33,37,40 and registryinformation (n = 4).34,36,38,39
Outcome Assessment
Outcomes included infectious (n = 7),atopic (n = 2), autoimmune (n = 2),and neurodevelopmental (n = 3)conditions, neoplasms (n = 1), and all-
cause morbidity (n = 2) and mortality(n = 2) (Table 5). Infections orinfectious conditions includedinfluenza, pneumonia, otitis media,sepsis, acute respiratory infections,gastrointestinal infections, viralinfections, and all-cause infection-related primary care contact. Atopicconditions included asthma.Autoimmune conditions includedceliac disease, ulcerative colitis,Crohn disease, juvenile arthritis,Sjögren syndrome, vasculitis,reactive arthropathy, idiopathicthrombocytopenic purpura, type-1diabetes, Bell palsy, and Guillain-Barré syndrome.Neurodevelopmental conditionsincluded epilepsy, autism spectrumdisorder, intellectual disability, andsensory disorders. All-causemorbidity outcomes included 1-yearall-cause hospitalization, 3-year all-cause hospitalization, 5-year all-causehospitalization, urgent and inpatienthealth services used, and pediatriccomplex chronic conditions.International Classification ofDiseases (ICD) clinical diagnosiscodes were used in the majority ofstudies (n = 5) to identify outcomes.
Given the small number of studies inwhich similarly defined outcomeswere addressed, meta-analyses weredeemed not possible.
Confounder Assessment
Among the 9 included studies, severalmaternal and child characteristicswere included as potentialconfounders (Supplemental
TABLE 3 Results of Risk-of-Bias Assessment for RCTs
RCTsa Risk ofBiasb
Selection Bias PerformanceBias
AttritionBias
DetectionBias
ReportingBias
RandomSequenceGeneration
AllocationConcealment
Blinding of Participants andPersonnel and Other Potential
Threatsto Validity
IncompleteOutcomeData
Blinding of OutcomeAssessment and Other Potential
Threatsto Validity
SelectiveOutcomeReporting
Bischoffet al41
(2015)
High Low Low Low Low High High
a RCTs were assessed using the Cochrane risk-of-bias tool. Each risk of bias item receives a judgement on risk of bias.b Risk of bias judgement given by algorithm.31
4 FOO et al by guest on January 12, 2021www.aappublications.org/newsDownloaded from
Table 11). Maternal characteristicsincluded maternal age (n = 6),ethnicity (n = 2), place of birth(n = 3), place of residence (n = 3),socioeconomic status and income(n = 4), education (n = 3), BMI (n = 2),parity (n = 5), medical comorbidities(n = 5), pregnancy complications (n =3), multiple gestations and/or births(n = 3), smoking during pregnancy(n = 4), season of conception (n = 2),and gestational age (n = 2). Childcharacteristics mostly included sex(n = 4). Other characteristics, such asmarital status, calendar year ofconception, use of antenatal care,
medication use, the child’s ethnicity,and other birth outcomes, wereless commonly controlled for asconfounders (n = 1) (SupplementalTable 11). One study accounted forthe potential influence of childhoodinfluenza immunization by censoringat age at influenza vaccination.33
Infectious Conditions
In the 2 studies in which researchersexamined influenza infection,infection status was ascertainedeither by a positive result by directfluorescent antibody test (forlaboratory-confirmed influenza)40 or
by using primary or secondarydiagnostic codes for (1) influenzaalone or (2) influenza andpneumonia.36 Outcome measureswere expressed as vaccineeffectiveness (VE; calculated as [1 2odds ratio comparing the odds ofinfection in exposed versusunexposed] 3 100%) or crudeincidence rates for influenza infectionamong children exposed to IIV inutero versus unexposed. Benowitzet al40 assessed laboratory-confirmedinfluenza and did not identify anassociation between IIV exposure inutero and VE in infants aged$6 months (unadjusted VE: 241.4%;95% CI: 22257.4% to 91.5%)(Table 5). However, as noted byBenowitz et al,40 because of the smallsample size of infants aged $6months, there was low statisticalpower to assess VE. In a study thatfollowed infants #1 year of age, Fellet al36 observed incidence rates ofinfluenza that did not differ betweenchildren exposed to IIV in uterocompared with unexposed childrenfor each influenza time periodexamined, including the 2009A/H1N1 pandemic season (incidencerate ratio: 0.61; 95% CI: 0.32 to 1.17)and the post-2009 A/H1N1 pandemicperiod (adjusted incidence rate ratio[aIRR]: 1.05; 95% CI: 0.81 to 1.37).Incidence rates for influenza andpneumonia were significantly higheramong infants exposed to IIV in uterocompared with unexposed infants inthe post-2009 A/H1N1 pandemicperiod (aIRR: 1.17; 95% CI: 1.05 to1.31). However, incidence rates forinfluenza and pneumonia did notdiffer significantly during the 2009A/H1N1 pandemic season (aIRR:1.04; 95% CI: 0.84 to 1.29) (Table 5).
Researchers of two studies assessedinfection-related primary care contact(fever, symptoms of infection of $1organ system, or prescriptions forinfectious symptoms) by examiningmedical records given by primarycare providers35 and infections(common cold, pharyngitis, otitis,
FIGURE 1Flow diagram of study selection process for systematic review of the literature on early childhoodhealth outcomes associated with in utero exposure to influenza vaccines.
PEDIATRICS Volume 146, number 2, August 2020 5 by guest on January 12, 2021www.aappublications.org/newsDownloaded from
TABLE4Characteristicsof
StudiesIncluded
inaSystem
aticReview
oftheLiterature
onEarlyChildhood
Health
Outcom
esAssociated
With
InUteroExposure
toInfluenzaVaccines
Author(s)(y),Country
StudyDesign
Ascertainm
entof
Exposure
Type
ofVaccine
StudyPeriod
Ageof
Follow-
upNo.Participants
Trimesterof
Exposure,n
(%)
Ascertainm
entof
Outcom
eOutcom
e(s)
Exposed
Unexposed
First
Second
Third
Pandem
icinfluenza
vaccine
Bischoffet
al41
(2015),D
enmark
Nested
RCT
Random
allocation
MF59-adjuvanted
pandem
icA/H1N1
influenzavaccine
2009–2010
0–1y
51332
Notspecified
Notspecified
Notspecified
Parent-reported
daily
diarycards
review
edby
research
doctor
Infections
(com
mon
cold,
pharyngitis,otitis,
pneumonia,fever,and
gastrointestinal
infection)
Ludvigsson
etal34
(2015),Sweden
Prospectivecohort
Register
AS03-adjuvanted
pandem
icA/H1N1
influenzavaccine
October2,2009,
toNovember
26,2010
0–6.4y
41183
234317
Notspecified
Notspecified
Notspecified
Deathregister
Mortality
vanderMaaset
al35
(2016),
Netherlands
Retrospectivecohort
Self-report
MF59-adjuvanted
pandem
icA/H1N1
influenzavaccine
November2009
toDecember
2009
0–1y
1357
669
—1357
(100)across
thesecond
andthird
trimester
Register
andmedical
records
Infection-relatedprimary
care
contact(fever,
symptom
sof
infection
of$1organsystem
,or
prescriptions
for
infectious
symptom
s)Fellet
al36(2016),
Canada
Retrospectivecohort
Register
Pandem
icA/H1N1
influenzavaccinea
November2,
2009
toOctober
31,2010
0–1y
36044
81302
Notspecified
Notspecified
Notspecified
Medical
records
Influenza,combinationof
pneumonia
and
influenza
Hviid
etal38(2017),
Denm
ark
Retrospectivecohort
Register
AS03-adjuvanted
pandem
icA/H1N1
influenzavaccine
November2,
2009
toMarch
31,2010
0–5y
6311
55048
349(5.5)
5962
(94.5)
across
thesecond
andthird
trimester
Register
andmedical
records
Hospitalizations,
infectious
diseases,
autoimmunediseases,
neurologicdiseases,
behavioral
disorders
Walsh
etal39(2019),
Canada
Retrospectivecohort
Register
Pandem
icA/H1N1
influenzavaccinea
November2,
2009
toOctober
31,2010
0–5y
31295
72954
Notspecified
Notspecified
Notspecified
Medical
records
Infectious
diseases,atopic
diseases,n
eoplasms,
sensorydisorders,
urgent
andinpatient
health
services
use,
complex
chronic
conditions,mortality
Seasonal
influenza
vaccine
Benowitz
etal40
(2010),U
nited
States
Matched
case-
control
Medical
records
IIVOctober1,2000
toApril30,
2009
0–1y
113b
193
—8(22.2)
28(77.8)
Direct
fluorescent
antibodytest
Laboratory-confirm
edinfluenza
vanSanten
etal33
(2013),U
nited
States
Retrospectivecohort
Medical
records
TrivalentIIV
June
2,2002
toDecember31,
2009
0–1y
2416
7391
Notspecified
Notspecified
Notspecified
Medical
records
Acuteotitismedia,
medicallyattended
acuterespiratory
infections
Zerboet
al37(2017),
UnitedStates
Prospectivecohort
Medical
records
IIVc
2000–2010
0–15
y45
231
151698
13477(29.8)
17475(38.6)
16095(35.6)
Medical
records
Autismspectrum
disorder
IIV,inactivated
influenzavaccine;—,indicates
noparticipants
intheexposure
group.
aStudydidnotdistinguishbetweennon-adjuvanted
pandem
icinfluenzavaccine(targetedat
pregnant
wom
en)andAS03-adjuvantedpandem
icinfluenzavaccine(targetedat
thegeneralpopulation).
bNumberof
case
participants
(infants
hospitalized
forlaboratory-confirm
edinfluenza).
cStudyincluded
the2009
A/H1N1
pandem
icyear;investigatorsdidnotdistinguishbetweentheseasonal
trivalentinfluenzavaccinefrom
thepandem
icmonovalentvaccineduring
thisperiod
oftim
e.
6 FOO et al by guest on January 12, 2021www.aappublications.org/newsDownloaded from
TABLE 5 Adjusted Effect Estimates of Early Childhood Health Outcomes Associated With In Utero Exposure to Influenza Vaccine, by Pandemic and SeasonalInfluenza Vaccines
Author(s) (y) Outcome Assessed Effect Estimate forVaccination at Any
Time During Pregnancy
Effect Estimate by Trimester
First Trimester Second Trimester Third Trimester
PandemicinfluenzavaccineBischoff
et al41
(2015)
All infections (common cold,pharyngitis, otitis, pneumonia,fever, gastrointestinal infection)
aIRR: 0.99 (0.84–1.18) — — —
Ludvigssonet al34
(2015)
Mortality aHR: 0.97 (0.69–1.36) vssibling control: aHR:0.78 (0.52–1.19)a
aHR: 0.86 (0.51–1.47)versus sibling control:aHR: 0.47 (0.22–1.01)a
aHR: 1.10 (0.69–1.76)versus sibling control:aHR: 1.44 (0.74–2.78)a
aHR: 0.93 (0.54–1.60)versus sibling control:aHR: 0.65 (0.30–1.39)a
van derMaaset al35
(2016)
Infection-related primary carecontact
aIRR: 1.07 (0.91–1.28) — — —
Fell et al36
(2016)Influenza, by season
2009 A/H1N1 pandemic season IRR: 0.61 (0.32–1.17) — — —
Post 2009 A/H1N1 pandemicperiod
aIRR: 1.05 (0.81–1.37) — — —
Pre-2010–2011 period aIRR: 1.08 (0.80–1.44) — — —
2010–2011 period aIRR: 0.88 (0.76–1.02) — — —
Post-2010–2011 period aIRR: 0.72 (0.50–1.04) — — —
Pre-2011–2012 period — — — —
Influenza and pneumonia, by season2009 A/H1N1 pandemic season aIRR: 1.04 (0.84–1.29) — — —
Post 2009 A/H1N1 pandemicperiod
aIRR: 1.17 (1.05–1.31) — — —
Pre-2010–2011 period aIRR: 1.07 (0.93–1.25) — — —
2010–2011 period aIRR: 0.99 (0.92–1.07) — — —
Post-2010–2011 period aIRR: 1.00 (0.85–1.17) — — —
Pre-2011–2012 period aIRR: 0.81 (0.38–1.70) — — —
Hviid et al38
(2017)1-y hospitalization aHR: 1.10 (0.89–1.37);
aRR: 1.15 (0.90–1.48)aHR: 0.94 (0.89–0.99); aRR: 0.93 (0.87–0.99)
3-y hospitalization aHR: 1.15 (0.97–1.37);aRR: 1.21 (0.98–1.50)
aHR: 0.95 (0.90–0.99); aRR: 0.96 (0.90–1.01)
5-y hospitalization aHR: 1.13 (0.96–1.32);aRR: 1.17 (0.94–1.45)
aHR: 0.95 (0.91–0.99); aRR: 0.93 (0.87–0.99)
Upper respiratory tract infections — aRR: 1.08 (0.80–1.46) aRR: 0.92 (0.85–0.99); aRR: 0.92 (0.81–1.03)b
Lower respiratory tract infections — aRR: 0.90 (0.63–1.28) aRR: 0.92 (0.84–1.00)Gastrointestinal infections aRR:1.03 (0.68–1.55) aRR: 0.84 (0.74–0.94); aRR: 0.84 (0.70–1.00)b
Meningitis — — aRR: 1.17 (0.61–2.24)Sepsis — — aRR: 1.96 (1.26–3.05); aRR: 1.96 (0.98–3.91)b
Viral infections — aRR: 1.20 (0.82–1.73) aRR: 0.91 (0.82–1.00)Other infections — aRR: 1.71 (1.08–2.73);
aRR: 1.71 (0.83–3.56)baRR: 0.92 (0.81–1.05)
Asthma — aRR: 1.50 (0.99–2.29) aRR: 1.02 (0.89–1.16)Celiac disease — — aRR: 0.81 (0.31–2.12)Crohn disease — — aRR: 1.24 (0.31–11.90)Ulcerative colitis — — aRR: 2.48 (0.41–14.82)Juvenile arthritis — — aRR: 0.60 (0.23–1.54)Sjögren syndrome aRR: 1.15 (0.24–5.53) aRR: 1.59 (1.04–2.44); aRR: 1.59 (0.82–3.11)b
Vasculitis — — — —
Reactive arthropathy — aRR: 0.80 (0.09–6.88) aRR: 1.40 (0.96–2.05)Idiopathic thrombocytopenicpurpura
— — aRR: 0.68 (0.15–3.05)
Idiopathic urticaria — — aRR: 1.03 (0.38–2.78)Type-1 diabetes — — aRR: 0.80 (0.23–2.77)Bell palsy — — aRR: 1.24 (0.34–4.57)Epilepsy — aRR: 1.01 (0.21–4.74) aRR: 0.86 (0.58–1.27)
PEDIATRICS Volume 146, number 2, August 2020 7 by guest on January 12, 2021www.aappublications.org/newsDownloaded from
pneumonia, and gastrointestinalinfection) or fever by parent-reporteddaily diary cards reviewed bya research doctor.41 Neither van derMaas et al35 (aIRR: 1.07; 95% CI: 0.91to 1.28) nor Bischoff et al41 (aIRR:0.99; 95% CI: 0.84 to 1.18) founda difference in incidence of infectionsbetween children of vaccinated andunvaccinated mothers in their studies(Table 5).
Studies in which upper respiratorytract infections, lower respiratorytract infections, and all-causeinfections were examined founda statistically significant reduction in
risk of upper respiratory tractinfections (adjusted rate ratio [aRR]:0.92; 95% CI: 0.85 to 0.99)38 and all-cause infections (aRR: 1.71; 95% CI:1.08 to 2.44)38 but not lowerrespiratory tract infections(Table 5).38,39 Hviid et al38 observedan inverse association with upperrespiratory tract infections and all-cause infections in children whosemothers were vaccinated withpandemic influenza vaccine in thesecond or third trimester and in thefirst trimester, respectively. However,after adjusting for multiplicity usinga Bonferroni correction, theseassociations were no longer
significant. Data from one of 2studies33,39 that investigated otitismedia in infants #1 year of agereported a lower absolute adjustedVE (calculated as 1 – the ratio of theincidence of otitis media in exposedversus unexposed children) forchildren whose mothers receiveda pneumococcal conjugate vaccinewhile pregnant (37.6%; 95% CI: 23.1to 49.4) than children whose mothersreceived a pneumococcal conjugatevaccine and trivalent IIV whilepregnant (47.9%; 95% CI: 42.0 to53.3), as compared with the childrenwhose mothers received no vaccinesduring pregnancy.33 The second
TABLE 5 Continued
Author(s) (y) Outcome Assessed Effect Estimate forVaccination at Any
Time During Pregnancy
Effect Estimate by Trimester
First Trimester Second Trimester Third Trimester
Guillain-Barré syndrome — — —
Autism spectrum disorder — — aRR: 1.22 (0.79–1.86)Intellectual disability — — aRR: 0.66 (0.28–1.56)
Walsh et al39
(2019)Upper respiratory tract infections aIRR: 1.01 (0.98–1.03) — — —
Lower respiratory tract infections aIRR: 0.99 (0.95–1.03) — — —
Gastrointestinal infections aIRR: 0.94 (0.91–0.98);aIRR: 0.94 (0.88–1.00)b
— — —
Otitis media aIRR: 1.03 (1.00–1.06) — — —
All infections aIRR: 1.01 (0.98–1.03) — — —
Asthma aHR: 1.05 (1.02–1.09);aHR: 1.05 (1.00–1.11)b
— — —
Neoplasms aHR: 1.12 (0.79–1.59) — — —
Sensory disorders aHR: 0.94 (0.67–1.33) — — —
Urgent and inpatient healthservices used
aIRR: 0.99 (0.98–1.01) — — —
Pediatric complex chronicconditions
aRR: 0.98 (0.80–1.20) — — —
5-y mortality aHR: 0.83 (0.64–1.08) — — —
SeasonalinfluenzavaccineBenowitz
et al40
(2010)
Laboratory-confirmed influenza VE: 241.4% (22257.4%to 91.5%)
— — —
van Santenet al33
(2013)
Acute otitis media aVE: 47.9% (42.0% to53.3%)
— — —
Medically attended acuterespiratory infections
aVE: 39.6% (31.6% to46.7%)
— — —
Zerbo et al37
(2017)Autism spectrum disorder aHR: 1.10 (1.00–1.21) aHR: 1.20 (1.04–1.39) aHR: 1.03 (0.90–1.19) aHR: 1.03 (0.90–1.20)
aIRR, adjusted incidence rate ratio; aHR, adjusted hazard ratio; aRR, adjusted rate ratio; aVE, adjusted vaccine effectiveness; VE, unadjusted vaccine effectiveness; —, not applicable.a Overall estimates are compared with unexposed children; an additional comparison with unexposed siblings also provided.b Adjusted for multiplicity using Bonferroni correction.
8 FOO et al by guest on January 12, 2021www.aappublications.org/newsDownloaded from
study, by Walsh et al,39 followedoffspring #5 years of age and foundno difference in incidence ratesbetween children exposed to IIV inutero and unexposed children (aIRR:1.03; 95% CI: 1.00 to 1.06). Walshet al39 and Hviid et al38 each observeda statistically significant reduction inthe risk of gastrointestinal infections(adjusted hazard ratio [aHR]: 0.94;95% CI: 0.91 to 0.98 and aRR: 0.84;95% CI: 0.74 to 0.94, respectively).Hviid et al38 observed this associationin children whose mothers werevaccinated in either the second orthird trimester but not in the firsttrimester. Second or third trimesterprenatal influenza vaccination wasalso associated with a significantincrease in risk of sepsis (aRR: 1.96;95% CI: 1.26 to 3.05).38 However,after taking multiple comparisonsinto account using Bonferroni-corrected CIs, associations forgastrointestinal infections and sepsiswere not significant and could havebeen due to chance (Table 5).38,39
Atopic, Autoimmune, andNeurodevelopmental Conditions
In the 2 studies in which asthma wasexamined, asthma status wasidentified from a regional asthmadatabase39 or by using primary orsecondary ICD diagnostic codes.38,39
Walsh et al39 reported a small, butsignificant, increase in asthma amongchildren exposed to IIV in uterocompared with unexposed children(aHR: 1.05; 95% CI: 1.02 to 1.09)(Table 5). However, results were nolonger statistically significant afteradjusting for multiplicity usingBonferroni correction (aHR: 1.05;95% CI: 1.00 to 1.11).39 Hviid et al38
reported no significant differencein asthma for first trimestervaccination (aRR: 1.50; 95% CI: 0.99to 2.29) or second or third trimestervaccination (aRR: 1.02; 95% CI: 0.89to 1.16).
Estimates on rates of autismspectrum disorder were provided in 2studies, of which 1 group evaluated
pandemic influenza vaccine39 and theother evaluated seasonal influenzavaccine.37 For both studies, autismspectrum disorder was identifiedusing ICD diagnostic codes. Zerboet al37 reported a slightly elevatedrisk of autism spectrum disorder afterprenatal influenza vaccination in thefirst trimester (aHR: 1.20; 95% CI:1.04 to 1.39) but not in the second orthird trimester (Table 5). However,this association was no longersignificant after adjusting formultiplicity using a Bonferronicorrection (P = .1). Hviid et al38 foundno significant association between IIVexposure in utero and autismspectrum disorder. Additionally, Hviidet al38 observed an increase of risk inSjögren syndrome, only after prenatalinfluenza vaccination in the second orthird trimester (aRR: 1.59; 95% CI:1.04 to 2.44) but not in the firsttrimester. After adjusting formultiplicity using a Bonferronicorrection, this association forSjögren syndrome was no longersignificant (aRR: 1.59; 95% CI: 0.82to 3.11).
Across all studies, there were noother significant associationsbetween prenatal influenzavaccination and celiac disease,38
Crohn disease,38 ulcerative colitis,38
juvenile arthritis,38 vasculitis,38
reactive arthropathy,38 idiopathicthrombocytopenic purpura,38
idiopathic urticaria,38 type-1diabetes,38 Bell palsy,38 epilepsy,38
Guillain-Barré syndrome,38
intellectual disability,38 neoplasms,39
and sensory disorders (Table 5).39
All-Cause and Nonspecific ChildhoodMorbidity
All-cause childhood morbidityoutcomes included all-causehospitalizations and urgent careservices; researchers in 1 studyexamined a nonspecific outcome,including a complex of pediatricchronic conditions.39 Walsh et al39
found no significant associationsbetween IIV exposure in utero and
urgent and inpatient health servicesused39 or the nonspecific complex ofchronic conditions (Table 5).39 Hviidet al38 observed a statisticallysignificant reduction in the risk of1-year all-cause hospitalization (aHR:0.94; 95% CI: 0.89 to 0.99), 3-year all-cause hospitalization (aHR: 0.95; 95%CI: 0.90 to 0.99), and 5-year all-causehospitalization (aHR: 0.95; 95% CI:0.91 to 0.99) in children whosemothers were vaccinated in thesecond or third trimester.
Pediatric Mortality
Pediatric mortality was defined asdeath occurring from birth through5 years of age39 or from 7 days to4.6 years of age.34 No significantassociations were identified in the 2studies that examined mortality as anoutcome. Although Walsh et al39
reported a reduced associationbetween pandemic influenza vaccinegiven during pregnancy and pediatricmortality (aHR: 0.83; 95% CI: 0.64 to1.08), this result was not statisticallysignificant (Table 5). Similarly,Ludvigsson et al34 reported nosignificant association betweenpandemic influenza vaccine duringpregnancy and pediatric mortalityoverall (aHR: 0.97; 95% CI: 0.69 to1.36) or by trimester of vaccination(first trimester: aHR: 0.86; 95% CI:0.51 to 1.47; second trimester: aHR:1.10; 95% CI: 0.69 to 1.76; thirdtrimester: aHR: 0.93; 95% CI: 0.54 to1.60). Secondary analyses, usingunvaccinated siblings as controls, alsorevealed no significant associations(overall: aHR: 0.78; 95% CI: 0.52 to1.19; first trimester: aHR: 0.47; 95%CI: 0.22 to 1.01; second trimester:aHR: 1.44; 95% CI: 0.74 to 2.78; thirdtrimester: aHR; 0.65; 95% CI: 0.30 to1.39).34
Risk of Bias
For observational studies, risk of biasscores ranged from 6 to 8 on theNewcastle–Ottawa scale, of which 4studies were deemed to be at low riskof bias,34,36,38,39 and 4 studies weredeemed to be at moderate-high risk
PEDIATRICS Volume 146, number 2, August 2020 9 by guest on January 12, 2021www.aappublications.org/newsDownloaded from
of bias (Tables 1–3).33,35,37,40
Common causes of potential biasincluded inadequaterepresentativeness of the exposedcohort (n = 3)33,35,37 andinadequately described follow-up ofexposed and nonexposed cohorts (n =6). The 1 RCT included was deemedto be at high risk of bias because ofthe lack of blinding of outcomeassessment (detection bias) andinadequate ascertainment ofoutcomes (reporting bias).41
DISCUSSION
Although there has been increasinginterest in the potential impacts of IIVexposure in utero on later childhealth, we identified relatively fewstudies in which health outcomesthrough the age of 5 years have beenevaluated. In this systematic review,we summarized results from 9studies including information on over750 000 children, 163 924 of whomwere exposed to IIV in utero.Researchers in 2 studies suggestedlower risk of upper respiratory tractinfection, all-cause infections, all-cause hospitalization, andgastrointestinal infection associatedwith pandemic IIV exposure in utero.While the data from some studiessuggested a potential increase in therisk of asthma, sepsis, and Sjögrensyndrome after exposure to pandemicIIV in utero and an increased risk ofautism spectrum disorder afterexposure to seasonal IIV in utero,after adjusting for multiplecomparisons using Bonferroni-corrected CIs, these associations wereno longer statistically significant.
Narrative synthesis of these fewstudies indicates there is limitedevidence evaluating health outcomesthrough the age of 5 years afterexposure to IIV in utero, particularlyfor seasonal IIVs. Existing studiesassessed a range of outcomes and themajority examined exposure topandemic influenza vaccines. Only 3studies on seasonal influenza
vaccines in children were identified,and these were prone to bias;additional high-quality studies arewarranted. Furthermore, givenseasonal IIV is recommended in alltrimesters of pregnancy and fetaldevelopment varies by gestationalage, outcomes should be assessedaccording to gestational age atvaccination. Only 3 studies assessedoutcomes by trimester of vaccination,of which 1 study combined secondand third trimesters. The number ofvaccinated individuals, particularly inthe first trimester, was small andconsequently limited the statisticalpower to detect differences betweenthe children in the exposed andunexposed group. Differences instudy quality, exposureascertainment, vaccine type (ie,pandemic or seasonal, adjuvanted ornonadjuvanted, monovalent ortrivalent), and study outcomes andoutcome ascertainment, made itdifficult to compare results acrossstudies and precluded statisticalpooling of results. These differencesmay have also influenced thereliability of findings. For example,diagnoses recorded in medicalrecords and not using a validatedstandardized clinical assessmentcould lead to potential outcomemisclassification.
Importantly, while the potentialconfounding influence of maternalage, parity, and pre-existing medicalconditions was accounted for in moststudies, the study by van Santenet al33 was the only one thatfactored for receipt of childhoodimmunizations as a potentialconfounding variable by censoringchildren after receiving their owninfluenza vaccine.33 No study factoredfor receipt of other recommendedchildhood vaccines. Given that receiptof vaccines during pregnancy may bepredictive of childhood vaccination aswell as other health behaviors,44 it ispossible that residual bias in theobservational studies identifiedmay have influenced findings,
especially the observed protectiveassociations. Future studies shouldaim to account for childhoodimmunization status as a potentialconfounding variable.
Finally, there was little geographicvariation in the geographic location ofstudies identified. All included studieswere conducted in high-incomecountries in North America orEurope, and thus these findings maynot generalize to children in low andmiddle-income countries, whosepopulation demographics and riskprofiles differ markedly. Research onthe safety of influenza vaccinationduring pregnancy from low andmiddle-income countries would beuseful for guiding future vaccinepolicies and programs in thesesettings.
CONCLUSIONS
Maternal influenza vaccination isa growing public health tool forimproving the health of mothers andtheir infants. Despite long-standingrecommendations, maternal influenzaimmunization policies were notwidely adopted until the 2009influenza A/H1N1 pandemic, and, asidentified as part of this review, thelong-term health effects of in uteroexposure of influenza vaccines inchildren .6 months of age areunderinvestigated. We identifiedrelatively few studies in which earlychildhood health outcomes wereevaluated in children aged.6 months of age in maternallyvaccinated and unvaccinatedchildren, and the same outcomeswere rarely measured in the fewexisting studies. This made formalmeta-analyses impractical. Althoughour review indicates that exposure toIIV in utero is not associated withadverse health outcomes inchildhood, additional epidemiologicalstudies of early childhood healthoutcomes after maternal influenzavaccination are still needed toaddress this gap. Future well-
0 FOO et al1 by guest on January 12, 2021www.aappublications.org/newsDownloaded from
controlled research in which seasonalIIV administered in differenttrimesters and in different settings isconsidered is required to providea stronger evidence-base for the long-term safety of maternal influenzavaccination. Notwithstanding theneed for additional research in thisarea, the results of the studies to-datehave not revealed any adverse effectof maternal influenza vaccination onchildhood health outcomes during thefirst 5 years. These findings are
reassuring and can help supporthealth care providers and pregnantwomen in making decisions aboutinfluenza vaccination during pregnancy.
ACKNOWLEDGMENTS
The authors would like toacknowledge contributions made byMs Diana Blackwood, a researchlibrarian of the Faculty of HealthSciences, who provided guidancewith the literature searchstrategy.
ABBREVIATIONS
A/H1N1: influenza A virussubtype H1N1
aHR: adjusted hazard ratioaIRR: adjusted incidence rate ratioaRR: adjusted rate ratioCI: confidence intervalIIV: inactivated influenza vaccineICD: International Classification of
DiseasesRCT: randomized controlled trialVE: vaccine effectiveness
Mr Foo led the development and registration of the original protocol, performed data collection, analysis, and interpretation of findings, drafted the initial
manuscript, and reviewed and revised the manuscript critically for important intellectual content; Dr Regan conceptualized and designed the study, contributed to
the data collection and analysis and interpretation of data, and revised the manuscript critically for important intellectual content; Dr Sarna contributed to the
development of the original protocol, contributed to data collection, analysis and interpretation of data, and revised the manuscript critically for important
intellectual content; Drs Fell, Moore, and Pereira advised on the development of the original protocol, contributed to the interpretation of results, and revised the
manuscript critically for important intellectual content; and all authors have approved the final version of the manuscript for publication and agree to be
accountable for all aspects of the work related to the accuracy or integrity of the research.
DOI: https://doi.org/10.1542/peds.2020-0375
Accepted for publication May 7, 2020
Address correspondence to Damien Y.P. Foo, School of Public Health, Curtin University, GPO Box U1987, Perth 6845, Western Australia. E-mail: damien.foo@
postgrad.curtin.edu.au
PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).
Copyright © 2020 by the American Academy of Pediatrics
FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.
FUNDING: Supported by a Curtin University Postgraduate Award, a postgraduate top-up scholarship from the Wesfarmers Centre of Vaccines & Infectious Diseases,
Telethon Kids Institute (to Mr Foo), and the National Health and Medical Research Council (GNT114150 to Drs Regan and Pereira; GNT1099655 and GNT1173991 to Dr
Pereira; GNT1034254 to Dr Moore).
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
REFERENCES
1. Zhou F, Trieu M-C, Davies R, Cox RJ.Improving influenza vaccines:challenges to effectiveimplementation. Curr Opin Immunol.2018;53:88–95
2. Blyth CC, Macartney KK, Hewagama S,et al. Influenza epidemiology, vaccinecoverage and vaccine effectiveness inchildren admitted to sentinel Australianhospitals in 2014: the InfluenzaComplications Alert Network (FluCAN).Euro Surveill. 2016;21(30):25–33
3. Zaman K, Roy E, Arifeen SE, et al.Effectiveness of maternal influenzaimmunization in mothers and infants[published correction appears in N EnglJ Med. 2009;360(6):648]. N Engl J Med.2008;359(15):1555–1564
4. Macdonald N, Bortolussi R. Protectingyoung babies from influenza. PaediatrChild Health. 2009;14(9):612–617
5. Halasa NB, Gerber MA, Chen Q, WrightPF, Edwards KM. Safety andimmunogenicity of trivalent inactivatedinfluenza vaccine in infants. J Infect Dis.2008;197(10):1448–1454
6. World Health Organization. Vaccinesagainst influenza WHO position paper –November 2012. Wkly Epidemiol Rec.2012;87(47):461–476
7. Orije MRP, Maertens K, Corbière V, et al.The effect of maternal antibodies on thecellular immune response after infantvaccination: a review. Vaccine. 2020;38(1):20–28
8. Steinhoff MC, Omer SB, Roy E, et al.Influenza immunization inpregnancy–antibody responsesin mothers and infants. N EnglJ Med. 2010;362(17):1644–1646
9. Sperling RS, Engel SM, Wallenstein S,et al. Immunogenicity of trivalentinactivated influenza vaccinationreceived during pregnancy orpostpartum. Obstet Gynecol. 2012;119(3):631–639
10. Jackson LA, Patel SM, Swamy GK, et al.Immunogenicity of an inactivatedmonovalent 2009 H1N1 influenzavaccine in pregnant women.J Infect Dis. 2011;204(6):854–863
PEDIATRICS Volume 146, number 2, August 2020 11 by guest on January 12, 2021www.aappublications.org/newsDownloaded from
11. Grohskopf LA, Sokolow LZ, Broder KR,Walter EB, Fry AM, Jernigan DB.Prevention and control of seasonalinfluenza with vaccines:recommendations of the advisorycommittee on immunization practices-United States, 2018–19 influenzaseason. MMWR Recomm Rep. 2018;67(3):1–20
12. Silverman N, Beigi R. ACOG committeeopinion no. 732: influenza vaccinationduring pregnancy. Obstet Gynecol. 2018;131(4):e109–e114
13. The Royal Australian and New ZealandCollege of Obstetricians andGynaecologists. Influenza VaccinationDuring Pregnancy (and in WomenPlanning Pregnancy). Melbourne,Australia: The Royal Australian and NewZealand College of Obstetricians andGynaecologists; 2017
14. Macias AE, Precioso AR, Falsey AR;Global Influenza Initiative. The GlobalInfluenza Initiative recommendationsfor the vaccination of pregnant womenagainst seasonal influenza. InfluenzaOther Respir Viruses. 2015;9(suppl 1):31–37
15. Regan AK, Mak DB, Hauck YL, Gibbs R,Tracey L, Effler PV. Trends in seasonalinfluenza vaccine uptake duringpregnancy in Western Australia:implications for midwives. WomenBirth. 2016;29(5):423–429
16. McCarthy EA, Pollock WE, Tapper L,Sommerville M, McDonald S. Increasinguptake of influenza vaccine by pregnantwomen post H1N1 pandemic:a longitudinal study in Melbourne,Australia, 2010 to 2014. BMC PregnancyChildbirth. 2015;15(1):53
17. Liu N, Sprague AE, Yasseen AS III, et al.Vaccination patterns in pregnantwomen during the 2009 H1N1 influenzapandemic: a population-based study inOntario, Canada. Can J Public Health.2012;103(5):e353–e358
18. Fabry P, Gagneur A, Pasquier J-C.Determinants of A (H1N1) vaccination:cross-sectional study in a population ofpregnant women in Quebec. Vaccine.2011;29(9):1824–1829
19. Dabrera G, Zhao H, Andrews N, et al.Effectiveness of seasonal influenzavaccination during pregnancy inpreventing influenza infection in
infants, England, 2013/14. Euro Surveill.2014;19(45):20959
20. Groom HC, Henninger ML, Smith N, et al.Influenza vaccination during pregnancy:influenza seasons 2002–2012, vaccinesafety datalink. Am J Prev Med. 2016;50(4):480–488
21. Kennedy ED, Ahluwalia IB, Ding H, Lu P-J,Singleton JA, Bridges CB. Monitoringseasonal influenza vaccinationcoverage among pregnant women inthe United States. Am J Obstet Gynecol.2012;207(suppl 3):S9–S16
22. Kahn KE, Black CL, Ding H, et al.Influenza and tdap vaccinationcoverage among pregnant women -United States, April 2018. MMWR MorbMortal Wkly Rep. 2018;67(38):1055–1059
23. Lane S, MacDonald NE, Marti M,Dumolard L. Vaccine hesitancy aroundthe globe: analysis of three years ofWHO/UNICEF Joint Reporting Formdata—2015–2017. Vaccine. 2018;36(26):3861–3867
24. Bratton KN, Wardle MT, Orenstein WA,Omer SB. Maternal influenzaimmunization and birth outcomes ofstillbirth and spontaneous abortion:a systematic review and meta-analysis.Clin Infect Dis. 2015;60(5):e11–e19
25. Nunes MC, Aqil AR, Omer SB, Madhi SA.The effects of influenza vaccinationduring pregnancy on birth outcomes:a systematic review and meta-analysis.Am J Perinatol. 2016;33(11):1104–1114
26. Zhang C, Wang X, Liu D, Zhang L, Sun X.A systematic review and meta-analysisof fetal outcomes following theadministration of influenza A/H1N1vaccination during pregnancy. IntJ Gynaecol Obstet. 2018;141(2):141–150
27. Polyzos KA, Konstantelias AA, Pitsa CE,Falagas ME. Maternal influenzavaccination and risk for congenitalmalformations: a systematic review andmeta-analysis. Obstet Gynecol. 2015;126(5):1075–1084
28. Jarvis JR, Dorey RB, Warricker FDM,Alwan NA, Jones CE. The effectiveness ofinfluenza vaccination in pregnancy inrelation to child health outcomes:systematic review and meta-analysis.Vaccine. 2020;38(7):1601–1613
29. Moher D, Liberati A, Tetzlaff J, AltmanDG; PRISMA Group. Preferred reportingitems for systematic reviews and meta-
analyses: the PRISMA statement. AnnIntern Med. 2009;151(4):264–269, W64
30. Desmeules R, Dorgan M, Campbell S.Acknowledging librarians’ contributionsto systematic review searching. J CanHealth Libr Assoc. 2016;37(2)
31. Higgins JPT, Green S, eds. CochraneHandbook for Systematic Reviews ofInterventions Version 5.2.0. London,United Kingdom: The CochraneCollaboration; 2011
32. Wells G, Shea B, O’Connell J. TheNewcastle-Ottawa Scale (NOS) forAssessing the Quality ofNonrandomised Studies in Meta-Analyses. Ottawa, Canada: The OttawaHospital; 2014
33. van Santen KL, Bednarczyk RA, Adjaye-Gbewonyo D, Orenstein WA, Davis R,Omer SB. Effectiveness ofpneumococcal conjugate vaccine ininfants by maternal influenzavaccination status. Pediatr Infect Dis J.2013;32(11):1180–1184
34. Ludvigsson JF, Ström P, Lundholm C,et al. Maternal vaccination againstH1N1 influenza and offspring mortality:population based cohort study andsibling design. BMJ. 2015;351:h5585
35. van der Maas N, Dijs-Elsinga J,Kemmeren J, van Lier A, Knol M, deMelker H. Safety of vaccination againstinfluenza A (H1N1) during pregnancy inthe Netherlands: results on pregnancyoutcomes and infant’s health: cross-sectional linkage study. BJOG. 2016;123(5):709–717
36. Fell DB, Wilson K, Ducharme R, et al.Infant respiratory outcomes associatedwith prenatal exposure to maternal2009 A/H1N1 influenza vaccination. PLoSOne. 2016;11(8):e0160342
37. Zerbo O, Qian Y, Yoshida C, Fireman BH,Klein NP, Croen LA. Association betweeninfluenza infection and vaccinationduring pregnancy and risk of autismspectrum disorder. JAMA Pediatr. 2017;171(1):e163609
38. Hviid A, Svanström H, Mølgaard-NielsenD, Lambach P. Association betweenpandemic influenza A(H1N1)vaccination in pregnancy and earlychildhood morbidity in offspring. JAMAPediatr. 2017;171(3):239–248
39. Walsh LK, Donelle J, Dodds L, et al.Health outcomes of young children
FOO et al12 by guest on January 12, 2021www.aappublications.org/newsDownloaded from
born to mothers who received 2009pandemic H1N1 influenza vaccinationduring pregnancy: retrospective cohortstudy. BMJ. 2019;366:l4151
40. Benowitz I, Esposito DB, Gracey KD,Shapiro ED, Vázquez M. Influenzavaccine given to pregnant womenreduces hospitalization due to influenzain their infants. Clin Infect Dis. 2010;51(12):1355–1361
41. Bischoff AL, Følsgaard NV, Vissing NH,Birch S, Brix S, Bisgaard H. Airway
mucosal immune-suppression inneonates of mothers receivingA(H1N1)pnd09 vaccination duringpregnancy. Pediatr Infect Dis J. 2015;34(1):84–90
42. Wells GA, Shea BOD, Peterson J, Welch V,Losos MTP. The Newcastle-Ottawa Scale(NOS) for assessing the quality ofnonrandomised studies in meta-analyses. 2019. Available at: www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed May 14, 2019
43. Higgins JPT, Sterne JAC, Savovi�c J, et al.A revised tool for assessing risk of biasin randomized trials. CochraneDatabase Syst Rev. 2016;10(suppl 1):29–31
44. Danchin MH, Costa-Pinto J, Attwell K,et al. Vaccine decision-making begins inpregnancy: correlation between vaccineconcerns, intentions and maternalvaccination with subsequent childhoodvaccine uptake. Vaccine. 2018;36(44):6473–6479
PEDIATRICS Volume 146, number 2, August 2020 13 by guest on January 12, 2021www.aappublications.org/newsDownloaded from
DOI: 10.1542/peds.2020-0375 originally published online July 27, 2020; 2020;146;Pediatrics
Fell and Annette K. ReganDamien Y.P. Foo, Mohinder Sarna, Gavin Pereira, Hannah C. Moore, Deshayne B.
Vaccines: A Systematic ReviewEarly Childhood Health Outcomes Following In Utero Exposure to Influenza
ServicesUpdated Information &
http://pediatrics.aappublications.org/content/146/2/e20200375including high resolution figures, can be found at:
Referenceshttp://pediatrics.aappublications.org/content/146/2/e20200375#BIBLThis article cites 39 articles, 2 of which you can access for free at:
Subspecialty Collections
_subhttp://www.aappublications.org/cgi/collection/vaccine:immunizationVaccine/Immunizationhttp://www.aappublications.org/cgi/collection/epidemiology_subEpidemiologybhttp://www.aappublications.org/cgi/collection/infectious_diseases_suInfectious Diseasefollowing collection(s): This article, along with others on similar topics, appears in the
Permissions & Licensing
http://www.aappublications.org/site/misc/Permissions.xhtmlin its entirety can be found online at: Information about reproducing this article in parts (figures, tables) or
Reprintshttp://www.aappublications.org/site/misc/reprints.xhtmlInformation about ordering reprints can be found online:
by guest on January 12, 2021www.aappublications.org/newsDownloaded from
DOI: 10.1542/peds.2020-0375 originally published online July 27, 2020; 2020;146;Pediatrics
Fell and Annette K. ReganDamien Y.P. Foo, Mohinder Sarna, Gavin Pereira, Hannah C. Moore, Deshayne B.
Vaccines: A Systematic ReviewEarly Childhood Health Outcomes Following In Utero Exposure to Influenza
http://pediatrics.aappublications.org/content/146/2/e20200375located on the World Wide Web at:
The online version of this article, along with updated information and services, is
http://pediatrics.aappublications.org/content/suppl/2020/07/22/peds.2020-0375.DCSupplementalData Supplement at:
by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397. the American Academy of Pediatrics, 345 Park Avenue, Itasca, Illinois, 60143. Copyright © 2020has been published continuously since 1948. Pediatrics is owned, published, and trademarked by Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it
by guest on January 12, 2021www.aappublications.org/newsDownloaded from